A Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety and Tolerability of ASP2215
PHASE1CompletedINTERVENTIONAL
Enrollment
24
Participants
Timeline
Start Date
October 23, 2015
Primary Completion Date
March 5, 2016
Study Completion Date
March 5, 2016
Conditions
Hepatic ImpairmentHealthy
Interventions
DRUG
ASP2215
oral
Trial Locations (1)
33014
Site US10001, Miami
All Listed Sponsors
lead
Astellas Pharma Global Development, Inc.
INDUSTRY
NCT02571816 - A Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety and Tolerability of ASP2215 | Biotech Hunter | Biotech Hunter